Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line
2008 (English)In: Biochemical and Biophysical Research Communications - BBRC, ISSN 0006-291X, Vol. 377, no 2, 489-494 p.Article in journal (Refereed) Published
HER2-specific affibody molecules in different formats have previously been shown to be useful tumor targeting agents for radionuclide-based imaging and therapy applications, but their biological effect on tumor cells is not well known. In this study, two dimeric ((ZHER2:4)2 and (ZHER2:342)2) and one monomeric (ZHER2:342) HER2-specific affibody molecules are investigated with respect to biological activity. Both (ZHER2:4)2 and (ZHER2:342)2 were found to decrease the growth rate of SKBR-3 cells to the same extent as the antibody trastuzumab. When the substances were removed, the cells treated with the dimeric affibody molecules continued to be growth suppressed while the cells treated with trastuzumab immediately resumed normal proliferation. The effects of ZHER2:342 were minor on both proliferation and cell signaling. The dimeric (ZHER2:4)2 and (ZHER2:342)2 both reduced growth of SKBR-3 cells and may prove therapeutically useful either by themselves or as carriers of radionuclides or other cytotoxic agents.
Place, publisher, year, edition, pages
2008. Vol. 377, no 2, 489-494 p.
Affibody molecule, Akt, Erk, HER2, Proliferation, Trastuzumab
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-100038DOI: 10.1016/j.bbrc.2008.10.027ISI: 000261301600031PubMedID: 18930032OAI: oai:DiVA.org:uu-100038DiVA: diva2:209276